

Rummaging Through Pharma's Attic: DNDi's model and patent pools



Robert Don
DNDi



Best Science for the Most Neglected

Best Science for the Most Neglected

DNDi Vision

A collaborative, patients' needs-driven, virtual, non-profit drug R&D organisation to develop new treatments against the most neglected communicable diseases



Best Science for the Most Neglected

Best Science for the Most Neglected

A Solid and Global Foundation

7 Founding Partners



- Indian Council for Medical Research (ICMR)
- Kenya Medical Research Institute (KEMRI)
- Malaysian MOH
- Oswaldo Cruz Foundation Brazil
- Medecins Sans Frontieres (MSF)
- Institut Pasteur France
- WHO/TDR (permanent observer)


DNDi
Drug for Neglected Diseases Initiative

Best Science for the Most Neglected

DNDi Objectives

- Primary:
 - **Deliver 6 - 8 new treatments by 2014** for leishmaniasis, sleeping sickness, Chagas disease, & malaria
 - **Establish a robust portfolio** for new generation of treatments
- Secondary:
 - **Use and strengthen existing capacity in Disease Endemic countries**
 - **Raise awareness and advocate for increased public responsibility**

DNDi
Drug for Neglected Diseases Initiative






Best Science for the Most Neglected

DNDi Pharma Partnerships

Best Science for the Most Neglected

Fexinidazole

CN1C=CN(C1)COC2=CC=C(C=C2)S

Clinical Candidate for Treatment of African Trypanosomiasis – Currently in Phase I

Originally developed by Hoechst
Partnered with Sanofi-aventis

DNDi
Drug for Neglected Diseases Initiative

Best Science for the Most Neglected

Ravuconazole

C14 α demethylase inhibitor
To enter clinical development for treatment of Chagas' Disease

Licensed from Eisai Co.

DNDi
Drug for Neglected Diseases Initiative

Best Science for the Most Neglected

Pediatric Benznidazole

Standard therapy for treatment of Chagas' Disease

Co-development with Lafepe (Brazil)

DNDi
Drug for Neglected Diseases Institute

Best Science for the Most Neglected

Oxaboroles for HAT

Under development as clinical candidates for treatment of Stage 2 African Trypanosomiasis

Licensed from ANACOR Inc.

Lead Optimization with SCYNEXIS Inc.

DNDi
Drug for Neglected Diseases Institute

Best Science for the Most Neglected

DNDi
Drug for Neglected Diseases Institute

Access to Compound Libraries

GSK
Merck & Co., Inc.
Scynexis Inc.
Pfizer
Genomics Institute of the Novartis
Research Foundation
Novartis Institute for Tropical Diseases
Basilea

Best Science for the Most Neglected

DNDi
Drug for Neglected Diseases Institute

Patent Pools

Best Science for the Most Neglected

Patent Pooling

- March 2009
 - GSK initiates patent pool for Neglected Tropical diseases 80+ families
- July 2009
 - Alnylam joins the pool with RNAi technology

DNDi
Drug for Neglected Diseases Initiative

Best Science for the Most Neglected

Patent Pool

In patent law, a **patent pool** is a consortium of at least two companies agreeing to cross-license patents relating to a particular technology.


The consortium may also license the patents to third parties

Pools usually have standardized licensing terms between partners and with third parties

Examples:

- The Radio Frequency Identification Domain RFID Consortium picked Via Licensing to administer its patent pool in September 2006 (20 companies)
- DVD Six Licensing Group – DVD Formats (9 Companies)

DNDi
Drug for Neglected Diseases Initiative



Pharma Patents

US Patent
"Antibacterial Agents"

A compound according to formula (I)

R1 and R1a are independently hydrogen; hydroxy; (C1-6)alkoxy unsubstituted or substituted by (C1-6)alkoxy, amino, piperidyl, guanidino or amidino any of which is optionally N-substituted by one or two (C1-6)alkyl, acyl or (C1-6)alkylsulphonyl groups, CONH2, hydroxy, (C1-6)alkylthio, heterocyclithio, heterocycloxy, arylthio, aryloxy, acylthio, acyloxy or (C1-6)alkylsulphonyloxy; (C1-6)alkoxy-substituted(C1-6)alkyl; halogen; (C1-6)alkyl; (C1-6)alkylthio; trifluoromethyl; trifluoromethoxy; nitro; cyano; azido; acyl; acyloxy; acylthio; (C1-6)alkylsulphonyl; (C1-6)alkylsulphoxide; arylsulphonyl; arylsulphoxide or an amino, piperidyl, guanidino or amidino group optionally N-substituted by one or two (C1-6)alkyl, acyl or (C1-6)alkylsulphonyl groups; provided that when Z1, Z2, Z3, Z4 and Z5 are CR1a or CH, then R1 is not hydrogen;

A is a substituted or unsubstituted 5 membered aromatic heterocyclic ring of formula (C);

wherein:

W1 and W2 are each independently selected from N, O, S, and CR8;

W3 is N or C;

W4 is N, O, S, or CR8;

each R8 is independently selected from hydrogen; hydroxy; halogen; trifluoromethyl; trifluoromethoxy; cyano; nitro; azido; acyl; acyloxy; acylthio; amino, mono- and di-(C1-6)alkylamino; and substituted and unsubstituted (C1-6)alkoxy, (C1-6)alkyl, (C3-7)cycloalkyl, aminocarbonyl, (C1-6)alkylthio, (C1-6)alkylsulphonyl, and (C1-6)alkylsulphoxide;

DNDi Best Science for the Most Neglected

Drugs for Neglected Diseases Initiative

Pharma patents

Pharma patents cover chemical space

They do not usually divulge useful SAR

What can a neglected diseases patent pool offer ?

Patent Pool Opportunities

Standardized license agreements

- Between patent holders
- With development partners
- Value current IP and improvements

“Throw it in the pool”

Access to “Intellectual Capital”

A mechanism to deal with IP contamination

Access to compounds/representative libraries

Best Science for the Most Neglected
DNDi
Drugs for Neglected Diseases Initiative

Patent Pool

The model is evolving

GSK Seeks partners and suggestions

Coordination by an independent third party is anticipated

An Opportunity exists to build a new collaborative model

Thank you!

DNDi Best Science for the Most Neglected
Drugs for Neglected Diseases Initiative